AINT yields 8.25% · JNJ yields 2.14%● Live data
📍 AINT pulled ahead of the other in Year 1
Combined, AINT + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AINT + JNJ for your $10,000?
AINT seeks long-term capital appreciation and absolute returns by employing a dollar-neutral strategy, taking long and short positions in large-cap US stocks from the S&P 500 (SPX), determined by a proprietary, adaptive AI Model. The model continuously ranks all 500 SPX stocks daily, integrating conventional and professional wisdom, fundamental signals, regulatory interpretations, NLP-extracted financial data, and advanced machine learning to provide dynamic stock rankings. Based on these rankings, the fund selects and weights the 1014 highest- and lowest-ranked stocks, respectively, with consideration to regulatory restrictions. The fund aims to balance long and short exposures and focus on relative performance and not market direction. Leverage may be used, increasing both gains and losses. The sub-adviser oversees the AI model for technical issues but does not alter outputs. Actual fund performance may differ from model results due to timing, fees, and cash holdings for operations.
Full AINT Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.